NY-ESO-1 expression in DCIS: A new predictor of good prognosis
R. Charles Coombes1, Otavia L. Caballero2,*, Sami. Shousha3, Sadaf Ghaem-Maghami3, Laura. Woodley-Barker3, Charlotte S. Wilhelm-Benartzi4, A. Munro Neville5
1Imperial College Healthcare NHS Trust & Imperial College, London, Hammersmith Hospital, London, UK
2Ludwig Collaborative Laboratory, Ludwig Institute for Cancer Research, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD USA
3Imperial College Healthcare NHS Trust & Imperial College, London, Charing Cross Hospital, London, UK
4Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK
5Ludwig Institute for Cancer Research, New York, USA
*Current affiliation: Orygen Biotecnologia, São Paulo, Brazil.
Charles Coombes, email: firstname.lastname@example.org
Keywords: CT antigen, breast cancer, immunotherapy, prognosis, ductal-carcinoma-in-situ (DCIS)
Received: January 18, 2017 Accepted: March 25, 2017 Published: April 28, 2017
Background: At present, it is difficult to predict which patients with ductal carcinoma-in-situ (DCIS) will subsequently develop frank invasive breast cancer (IDC). A recent survey by our group has shown that NY-ESO-1 and MAGEA are both expressed in DCIS. This study was aimed at determining whether expression of these antigens was related to the later development of IDC.
Results: 14 of 42 (33%) of patients developed invasive breast cancer during the follow up period. Only one of those DCIS cases that relapsed was positive for NYESO-1 at diagnosis. In contrast, DCIS samples of 15 of the 28 (54%) of those patients who remained disease-free expressed NY-ESO-1. (Permutation chi square p=0.0033).
Methods: We identified 42 patients with DCIS, and followed them up for more than 10 years. NY-ESO-1 and MAGEA were demonstrated by immunostaining as were CD8+ infiltrates on all sections together with the conventional markers, ER, PR, and HER2.
Conclusions: Expression of NY-ESO-1 may predict those patients who will not subsequently develop invasive breast cancer and could therefore potentially be helpful in defining prognosis in patients with DCIS.